{"id":"gemox-chemotherapy","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Neutropenia"},{"rate":"20-40%","effect":"Nausea and vomiting"},{"rate":"10-30%","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Gemcitabine is a nucleoside analog that inhibits DNA synthesis, while oxaliplatin is a platinum-based drug that cross-links DNA, causing cell death. This combination therapy aims to enhance the efficacy of each individual drug by targeting cancer cells from multiple angles.","oneSentence":"GEMOX chemotherapy combines gemcitabine and oxaliplatin to target rapidly dividing cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:37:59.557Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced pancreatic cancer"},{"name":"Advanced ovarian cancer"}]},"trialDetails":[{"nctId":"NCT06314334","phase":"PHASE2","title":"Screening Study of Combined Sequential Chemotherapy and Radiation Therapy for Early-stage NK/T-cell Lymphoma","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-03-04","conditions":"Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type","enrollment":210},{"nctId":"NCT03570892","phase":"PHASE3","title":"Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2019-05-07","conditions":"Non-Hodgkin Lymphoma","enrollment":331},{"nctId":"NCT07472621","phase":"","title":"Real-World Effectiveness and Safety of Glofitamab in Primary Refractory and Early Relapsed Diffuse Large B-Cell Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"Henan Cancer Hospital","startDate":"2026-03-10","conditions":"DLBCL - Diffuse Large B Cell Lymphoma","enrollment":20},{"nctId":"NCT02386397","phase":"PHASE1, PHASE2","title":"Activity of Regorafenib in Combination With Chemotherapy in Patients With Advanced Biliary Tract Cancer","status":"COMPLETED","sponsor":"Institut du Cancer de Montpellier - Val d'Aurelle","startDate":"2014-09","conditions":"Digestive Cancer","enrollment":66},{"nctId":"NCT04542824","phase":"PHASE1, PHASE2","title":"Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genmab","startDate":"2020-08-20","conditions":"Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma","enrollment":78},{"nctId":"NCT04628494","phase":"PHASE3","title":"A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genmab","startDate":"2021-01-13","conditions":"Diffuse Large B-cell Lymphoma","enrollment":484},{"nctId":"NCT07226752","phase":"PHASE3","title":"A Sub-study Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) in China","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genmab","startDate":"2022-10-08","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":72},{"nctId":"NCT05286814","phase":"PHASE2","title":"PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-10-24","conditions":"Metastatic Colorectal Cancer (Mcrc), Intrahepatic Cholangiocarcinoma (Icc), Intrahepatic Bile Duct Cancer","enrollment":70},{"nctId":"NCT07409428","phase":"PHASE3","title":"A Phase III Study of HMPL-760 in Combination With R-GemOx Versus Placebo in Combination With R-GemOx in Relapsed/Refractory DLBCL","status":"NOT_YET_RECRUITING","sponsor":"Hutchmed","startDate":"2026-03-10","conditions":"Relapsed/Refractory Diffuse Large B-Cell Lymphoma","enrollment":240},{"nctId":"NCT05430698","phase":"PHASE2","title":"PD-1 Antibody Plus GEMOX as Postoperative Adjuvant Therapy in Perihilar Cholangiocarcinoma","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2023-01-31","conditions":"Perihilar Cholangiocarcinoma","enrollment":62},{"nctId":"NCT07385989","phase":"PHASE2","title":"Golidocitinib Combined With P-GemOx Plus PD-1 Inhibitor Versus P-GemOx Plus PD-1 Inhibitor in First-Line Newly Diagnosed Advanced or Non-Nasal Extranodal NK/T-Cell Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"WEI XU","startDate":"2026-01-25","conditions":"Extranodal NK/T-cell Lymphoma","enrollment":40},{"nctId":"NCT06904170","phase":"PHASE2, PHASE3","title":"Durvalumab and Tremelimumab With or Without Hepatic Arterial Infusion of Chemotherapy in Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"UNICANCER","startDate":"2025-11-14","conditions":"Hepatocellular Carcinoma","enrollment":196},{"nctId":"NCT06313203","phase":"PHASE2","title":"HAI-Floxuridine, or SIRT, Combined With Gemox For Patients With Intra-Hepatic Cholangiocarcinoma Not Amenable to Resection (TOMCAT)","status":"RECRUITING","sponsor":"Oslo University Hospital","startDate":"2024-02-13","conditions":"Intrahepatic Cholangiocarcinoma, Chemotherapy Effect","enrollment":39},{"nctId":"NCT06829771","phase":"PHASE1, PHASE2","title":"Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2025-04-23","conditions":"Diffuse Large B Cell Lymphoma","enrollment":90},{"nctId":"NCT03092895","phase":"PHASE2","title":"A Study of SHR-1210 in Combination With Apatinib or Chemotherapy in Subjects With Advanced PLC or BTC","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2017-04-24","conditions":"Advanced Primary Liver Cancer, Advanced Biliary Tract Carcinoma","enrollment":157},{"nctId":"NCT05348811","phase":"PHASE2","title":"HAIC Combined With Donafenib and Sintilimab for Unresectable ICC","status":"COMPLETED","sponsor":"Zhongda Hospital","startDate":"2022-06-13","conditions":"Cholangiocarcinoma","enrollment":25},{"nctId":"NCT04425070","phase":"PHASE1, PHASE2","title":"A Study of Evaluating the Safety and Efficacy of ATG-010 Combined With Chemotherapy Sequential With ATG-010 Monotherapy Maintenance in Peripheral T- and NK/T-cell Lymphoma","status":"TERMINATED","sponsor":"Antengene Corporation","startDate":"2020-08-18","conditions":"Peripheral T-cell Lymphoma, NK/T-cell Lymphoma","enrollment":56},{"nctId":"NCT07304388","phase":"PHASE2","title":"HAIC Plus Systemic Chemotherapy, Lenvatinib and Toripalimab in Advanced ICC","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2023-02-10","conditions":"Intrahepatic Cholangiocarcinoma (Icc)","enrollment":96},{"nctId":"NCT03533582","phase":"PHASE3","title":"Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2018-05-24","conditions":"Childhood Hepatocellular Carcinoma, Childhood Malignant Liver Neoplasm, Fibrolamellar Carcinoma","enrollment":537},{"nctId":"NCT06230471","phase":"PHASE2","title":"Pembrolizumab With or Without Lenvatinib or Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2023-01-09","conditions":"Biliary Tract Neoplasms Immunotherapy","enrollment":60},{"nctId":"NCT07267078","phase":"PHASE2","title":"Tuvonralimab and Iparomlimab Based Regimens for the Neoadjuvant Treatment of Biliary Tract Cancer","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2025-05-25","conditions":"Biliary Tract Cancer","enrollment":45},{"nctId":"NCT06925516","phase":"PHASE2","title":"A Trial of Apatinib and Adebrelimab in Combination With Chemotherapy in Patients With Unresectable ICC","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2025-01-22","conditions":"Intrahepatic Cholangiocarcinoma (Icc)","enrollment":38},{"nctId":"NCT04891289","phase":"PHASE2","title":"Gemcitabine and Oxaliplatin Chemotherapy With or Without a Floxuridine and Dexamethasone Pump in People With Cholangiocarcinoma That Cannot Be Removed With Surgery","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2021-05-07","conditions":"Intrahepatic Cholangiocarcinoma","enrollment":164},{"nctId":"NCT03217097","phase":"NA","title":"MGMT-NET: O6-methylguanine-DNA Methyltransferase (MGMT) Status in Neuroendocrine Tumors: Predictive Factor of Response to Alkylating Agents","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2018-10-16","conditions":"Neuroendocrine Tumors","enrollment":116},{"nctId":"NCT06929624","phase":"PHASE3","title":"A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma","status":"RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2025-04-24","conditions":"Diffuse Large B-cell Lymphoma","enrollment":280},{"nctId":"NCT07208526","phase":"NA","title":"A Randomized Trial of Surgical Decision-Making Guided by TDTP-RECIST","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2025-12-01","conditions":"Intrahepatic Cholangiocarcinoma (Icc), Conversion Therapy, TDTP-RECIST","enrollment":270},{"nctId":"NCT04669496","phase":"PHASE2, PHASE3","title":"Phase II-III Clinical Trial of PD1 Antibody (Toripalimab), Lenvatinib and GEMOX Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2021-01-20","conditions":"Intrahepatic Cholangiocarcinoma, PD1 Antibody, Lenvatinib","enrollment":178},{"nctId":"NCT07053150","phase":"PHASE2","title":"A Prospective, Open-label, Exploratory Basket Trial to Evaluate the Efficacy and Safety of Sintilimab Combined With Pyrotinib ± Chemotherapy in Patients With Advanced Digestive System Tumors","status":"NOT_YET_RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-08-15","conditions":"Advanced Digestive System Tumor","enrollment":80},{"nctId":"NCT06370663","phase":"PHASE2","title":"First-line Treatment for Unresectable Locally Advanced Distal Cholangiocarcinoma Combining Radiotherapy and HAIC","status":"TERMINATED","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2024-04-01","conditions":"Intrahepatic Cholangiocarcinoma","enrollment":1},{"nctId":"NCT06601504","phase":"PHASE2","title":"Study of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hutchmed","startDate":"2024-11-05","conditions":"Relapsed/Refractory Diffuse Large B-Cell Lymphoma","enrollment":61},{"nctId":"NCT04668365","phase":"PHASE2","title":"Zanubrutinib Combined With Standard Chemotherapy in the Treatment for Patients With Diffuse Large B Cell Lymphoma","status":"SUSPENDED","sponsor":"Henan Cancer Hospital","startDate":"2020-12-25","conditions":"Diffuse Large B Cell Lymphoma, CD79A Gene Mutation, CD79B Gene Mutation","enrollment":59},{"nctId":"NCT05342194","phase":"PHASE3","title":"Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III Study","status":"RECRUITING","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2023-06-19","conditions":"Intrahepatic Cholangiocarcinoma","enrollment":480},{"nctId":"NCT04365036","phase":"PHASE3","title":"A Multicenter, Phase 3, Randomized Trial of Sequencial Chemoradiotherapy with or Without Toripalimab (PD-1 Antibody) in Newly Diagnosed Early-Stage Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (ENKTL)","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2020-05-03","conditions":"NK/T Cell Lymphoma Nos","enrollment":207},{"nctId":"NCT06208462","phase":"PHASE2","title":"Neoadjuvant Therapy of HAIC（GEMOX） Combined With Adebrelimab and Lenvatinib for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2024-01-19","conditions":"Intrahepatic Cholangiocarcinoma","enrollment":33},{"nctId":"NCT06852287","phase":"PHASE2","title":"Phase II Clinical Study of GemOX Hepatic Arterial Infusion Combined with Lenvatinib and Toripalimab for Advanced and Unresectable Intrahepatic Cholangiocarcinoma and Gallbladder Cancer","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2024-09-01","conditions":"Intrahepatic Cholangiocarcinoma (Icc), Gall Bladder Cancer","enrollment":33},{"nctId":"NCT04361331","phase":"PHASE2","title":"Two-cohort Study of Toripalimab(PD1)+Lenvatnib, or Gemox+Lenvatinib in Advanced Intrahepatic Cholangiocarcinoma","status":"COMPLETED","sponsor":"Shanghai Zhongshan Hospital","startDate":"2020-03-06","conditions":"Cholangiocarcinoma, Intrahepatic","enrollment":61},{"nctId":"NCT06718257","phase":"","title":"Chemotherapy Combined with Immunotherapy and Targeted Therapy in Cholangiocarcinoma","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2024-09-01","conditions":"Cholangiocarcinoma","enrollment":300},{"nctId":"NCT03366272","phase":"PHASE2, PHASE3","title":"Nivolumab With Gemcitabine, Oxaliplatin + Rituximab in r/r Elderly Lymphoma Patients","status":"COMPLETED","sponsor":"Universität des Saarlandes","startDate":"2017-12-05","conditions":"Lymphoma, Non-Hodgkin","enrollment":348},{"nctId":"NCT06792253","phase":"PHASE3","title":"Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma","status":"RECRUITING","sponsor":"BeBetter Med Inc","startDate":"2025-01-06","conditions":"Relapsed/Refractory Diffuse Large B-Cell Lymphoma","enrollment":416},{"nctId":"NCT06778902","phase":"PHASE2","title":"AZA Combined with R-GemOx for Elderly DLBCL Patients","status":"NOT_YET_RECRUITING","sponsor":"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","startDate":"2025-02-01","conditions":"DLBCL - Diffuse Large B Cell Lymphoma","enrollment":80},{"nctId":"NCT06654947","phase":"PHASE2","title":"A Single-arm, Open-label, Prospective Clinical Study of Surufatinib Combined With Immunotherapy and Chemotherapy for Unresectable or Metastatic Biliary Tract Cancer.","status":"NOT_YET_RECRUITING","sponsor":"Fujian Cancer Hospital","startDate":"2025-01","conditions":"Biliary Tract Cancer","enrollment":23},{"nctId":"NCT06192797","phase":"PHASE2","title":"Combined HAIC, Lenvatinib and Pucotenlimab As Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2024-06-11","conditions":"Cholangiocarcinoma Non-resectable","enrollment":36},{"nctId":"NCT04183712","phase":"PHASE2","title":"Target Therapy With GEMOX in Recectable Gallbladder Carcinoma Patients Monitored by ctDNA","status":"RECRUITING","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2020-06-01","conditions":"Gallbladder Carcinoma","enrollment":102},{"nctId":"NCT06573151","phase":"PHASE2","title":"Selinexor, Anti-PD-1 Antibody and P-GemOx Regimen in R/R NKTCL","status":"NOT_YET_RECRUITING","sponsor":"Ruijin Hospital","startDate":"2024-09-01","conditions":"Lymphoma","enrollment":28},{"nctId":"NCT05833815","phase":"PHASE2, PHASE3","title":"Addition of Everolimus to Standard of Care in Carcinoma Gallbladder","status":"RECRUITING","sponsor":"Banaras Hindu University","startDate":"2022-11-01","conditions":"Gallbladder Cancer","enrollment":56},{"nctId":"NCT06505486","phase":"","title":"GEMOX-HAIC Plus GEM-SYS in Combination With Lenvatinib and PD-1 Inhibitor for Large Unresectable ICC","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2024-07-10","conditions":"Intrahepatic Cholangiocarcinoma","enrollment":21},{"nctId":"NCT06423170","phase":"PHASE2","title":"A Single-arm Phase II Clinical Study of the Efficacy and Safety of Camrelizumab Combined With GEMOX for Unresectable GBCs","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2023-06-01","conditions":"Unresectable Gallbladder Cancer","enrollment":37},{"nctId":"NCT06362317","phase":"PHASE2","title":"Toripalimab With or Without Lenvatinib or Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2024-03-06","conditions":"Biliary Tract Neoplasms Immunotherapy","enrollment":300},{"nctId":"NCT06335927","phase":"PHASE2","title":"HAIC Combined With Cadonilimab and Regorafenib as 2nd-line Treatment for ICC","status":"RECRUITING","sponsor":"Fudan University","startDate":"2023-05-11","conditions":"Intrahepatic Cholangiocarcinoma","enrollment":45},{"nctId":"NCT06320301","phase":"PHASE2","title":"Adebrelimab and a TKI in Combination With GEMOX in First-line Treatment of Advanced Biliary Tract Cancers (BTC)","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2024-04-01","conditions":"Biliary Tract Cancer, Gemox Chemotherapy","enrollment":43},{"nctId":"NCT06164327","phase":"PHASE1","title":"Study of BEBT-908 Combined With Drugs in the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma","status":"UNKNOWN","sponsor":"BeBetter Med Inc","startDate":"2023-12-01","conditions":"Relapsed/Refractory Diffuse Large B-Cell Lymphoma","enrollment":75},{"nctId":"NCT05935579","phase":"PHASE2","title":"Durvalumab and Lenvatinib With or Without Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2022-12-14","conditions":"Biliary Tract Neoplasms, Immunotherapy","enrollment":40},{"nctId":"NCT06033118","phase":"PHASE1, PHASE2","title":"Gemox Combined With Anlotinib and Sintilimab in Advanced cHCC-ICC","status":"NOT_YET_RECRUITING","sponsor":"Sichuan University","startDate":"2023-10-01","conditions":"Combined Hepatocellular Cholangiocarcinoma","enrollment":25},{"nctId":"NCT04022005","phase":"PHASE2","title":"Chidamide + R-GemOx Regimen as Salvage Treatment for Transplant-ineligible Patients With Relapsed/Refractory DLBCL","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2019-06-19","conditions":"Lymphoma, Large B-Cell, Diffuse","enrollment":54},{"nctId":"NCT05156788","phase":"PHASE2","title":"Tislelizumab（Anti PD-1), Lenvatinib and GEMOX Transformation in the Treatment of Potentially Resectable, Locally Advanced Biliary Tract Cancer","status":"UNKNOWN","sponsor":"Shanghai Zhongshan Hospital","startDate":"2021-12-12","conditions":"Biliary Tract Cancer, PD-1 Antibody, Gemox","enrollment":40},{"nctId":"NCT05919095","phase":"PHASE2","title":"A Clinical Study of a Preoperative Translational Therapy for Unresectable Gallbladder Cancer","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2023-06-30","conditions":"Unresectable Gallbladder Cancer","enrollment":37},{"nctId":"NCT05036798","phase":"PHASE2","title":"Tislelizumab+Lenvatinib+Gemox Regiment for Potentially Resectable Locally Advanced Malignant Tumors of Biliary System.","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2021-09-17","conditions":"Potentially Resectable Locally Advanced Malignant Tumors of Biliary System","enrollment":30},{"nctId":"NCT05518318","phase":"PHASE3","title":"GLS-010 Monotherapy Versus Chemotherapy in Patients With Relapsed or Refractory Classical Hodgkin's Lymphoma (R/R cHL)","status":"UNKNOWN","sponsor":"Guangzhou Gloria Biosciences Co., Ltd.","startDate":"2022-09","conditions":"Classic Hodgkin's Lymphoma, Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma","enrollment":60},{"nctId":"NCT05254899","phase":"PHASE2","title":"Anti-PD-1 Antibody and P-GEMOX Chemotherapy Combined With Radiotherapy in High-risk Early-Stage ENKTL","status":"UNKNOWN","sponsor":"Chinese Academy of Medical Sciences","startDate":"2021-10-01","conditions":"Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type, Early-stage, High-Risk Cancer","enrollment":54},{"nctId":"NCT05247996","phase":"NA","title":"TACE Combined With \"Target Immune\" Therapy for First-line Treatment in the Treatment of Intrahepatic Cholangiocarcinoma","status":"UNKNOWN","sponsor":"The Central Hospital of Lishui City","startDate":"2022-03-01","conditions":"Intrahepatic Cholangiocarcinoma","enrollment":98},{"nctId":"NCT05244642","phase":"PHASE3","title":"A Phase III Study to Evaluate the Efficacy and Safety of Penpulimab in the Relapsed and Refractory Classical Hodgkin's Lymphoma","status":"RECRUITING","sponsor":"Akeso","startDate":"2022-02-15","conditions":"Hodgkin Disease Lymphoma","enrollment":60},{"nctId":"NCT03486678","phase":"PHASE2","title":"SHR-1210 in Combination With GEMOX in Patients With Advanced BTC","status":"COMPLETED","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2018-02-10","conditions":"Biliary Tract Cancer, Cholangiocarcinoma","enrollment":38},{"nctId":"NCT04961788","phase":"PHASE2","title":"Anti-PD1 Antibody Toripalimab Combined With Gemox as First-line Therapy in Late-stage Intrahepatic Cholangiocarcinoma","status":"UNKNOWN","sponsor":"Shanghai Zhongshan Hospital","startDate":"2021-07-01","conditions":"Intrahepatic Cholangiocarcinoma","enrollment":30},{"nctId":"NCT03951597","phase":"PHASE2","title":"Combined Therapy Using Oxaliplatin and Gemcitabine Chemotherapy, Lenvatinib and PD1 Antibody (JS001) for Patients With Advanced and Unresectable Intrahepatic Cholangiocarcinoma","status":"UNKNOWN","sponsor":"Shanghai Zhongshan Hospital","startDate":"2019-05-10","conditions":"Cholangiocarcinoma, Intrahepatic","enrollment":30},{"nctId":"NCT02085655","phase":"PHASE3","title":"PEG-ASP+Gemox Regimen and Thalidomide for NK/T Lymphoma","status":"UNKNOWN","sponsor":"Huiqiang Huang","startDate":"2013-04-25","conditions":"Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type","enrollment":264},{"nctId":"NCT04342936","phase":"PHASE3","title":"Study of Camrelizumab (SHR-1210) vs. Chemotherapy in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma","status":"UNKNOWN","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2020-07-17","conditions":"Classical Hodgkin Lymphoma","enrollment":56},{"nctId":"NCT04305288","phase":"","title":"Chemotherapy mFOLFIRINOX in Locally Advanced or Metastatic Cholangiocarcinoma","status":"UNKNOWN","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2016-01-01","conditions":"Cholangiocarcinoma of the Bile Duct","enrollment":100},{"nctId":"NCT04523402","phase":"PHASE2","title":"Neoadjuvant Therapy for Resectable Intrahepatic Cholangiocarcinoma With High Predict Risk of Lymph Node Metastasis","status":"UNKNOWN","sponsor":"Eastern Hepatobiliary Surgery Hospital","startDate":"2020-12-31","conditions":"Intrahepatic Cholangiocarcinoma Recurrent","enrollment":100},{"nctId":"NCT04506281","phase":"PHASE2","title":"PD1 Antibody (Toripalimab), GEMOX and Lenvatinib Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors","status":"UNKNOWN","sponsor":"Shanghai Zhongshan Hospital","startDate":"2020-08-10","conditions":"Cholangiocarcinoma, Intrahepatic","enrollment":128},{"nctId":"NCT00436280","phase":"PHASE2","title":"Chemotherapy for Participants With Lymphoma","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2007-02","conditions":"Lymphoma, Large Cell, Diffuse","enrollment":68},{"nctId":"NCT00602602","phase":"PHASE2","title":"Bevacizumab, Combination Chemotherapy, and Radiation Therapy in Treating Patients Undergoing Surgery For Locally Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2007-03","conditions":"Pancreatic Cancer","enrollment":19},{"nctId":"NCT02534337","phase":"PHASE2, PHASE3","title":"Gemcitabine Plus Oxaliplatin Versus Oxaliplatin Plus Fluorouracil/Leucovorin for Hepatocellular Carcinoma","status":"WITHDRAWN","sponsor":"Guangxi Medical University","startDate":"2015-09","conditions":"Hepatocellular Carcinoma","enrollment":""},{"nctId":"NCT03825328","phase":"PHASE2","title":"A Trial of NS/GEMOX Chemotherapy in Patients With Untreated Pancreatic Cancer ( HZ-NS/GEMOX-PC )","status":"UNKNOWN","sponsor":"Yanqiao Zhang","startDate":"2019-01-30","conditions":"Pancreatic Cancer","enrollment":30},{"nctId":"NCT02359162","phase":"PHASE3","title":"Efficacy and Safety Study of P-Gemox vs.EPOCH as First-line Chemotherapy to Treat NK/T-cell Lymphoma With Early Stage","status":"TERMINATED","sponsor":"Sun Yat-sen University","startDate":"2015-05","conditions":"Lymphoma, Extranodal NK-T-Cell","enrollment":50},{"nctId":"NCT02533323","phase":"PHASE2","title":"P-Gemox Regimen as First-line Chemotherapy in NK/T Lymphoma Patiens","status":"TERMINATED","sponsor":"Sun Yat-sen University","startDate":"2012-01","conditions":"Lymphoma, Extranodal NK-T-Cell","enrollment":50},{"nctId":"NCT02836847","phase":"PHASE2","title":"Molecularly Target Therapy With GEMOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma","status":"UNKNOWN","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2016-07","conditions":"Cholangiocarcinoma of the Extrahepatic Bile Duct, Gallbladder Cancer","enrollment":152},{"nctId":"NCT01562977","phase":"PHASE2","title":"Study to Evaluate Efficacy and Tolerance of R-GemOx in DLBCL and MCL","status":"COMPLETED","sponsor":"Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea","startDate":"2011-04","conditions":"Aggressive Lymphoma, Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma","enrollment":82},{"nctId":"NCT00361231","phase":"PHASE2","title":"Gemcitabine, Oxaliplatin in Combination With Bevacizumab in Biliary Tract and Gallbladder Cancer","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2006-05","conditions":"Biliary Tract Cancer, Gallbladder Adenocarcinoma","enrollment":35},{"nctId":"NCT01313377","phase":"PHASE3","title":"Gemcitabine Hydrochloride and Oxaliplatin or Observation in Treating Patients With Biliary Tract Cancer That Has Been Removed by Surgery","status":"COMPLETED","sponsor":"UNICANCER","startDate":"2009-07","conditions":"Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Liver Cancer","enrollment":190},{"nctId":"NCT02996617","phase":"PHASE4","title":"PEG-rhG-CSF in Patients With Non-Hodgkin Lymphoma Receiving Chemotherapy to Prevent Neutropenia","status":"UNKNOWN","sponsor":"Shandong Provincial Hospital","startDate":"2016-11","conditions":"Lymphoma,Non-Hodgkin","enrollment":240},{"nctId":"NCT00304135","phase":"PHASE2, PHASE3","title":"Fluorouracil, Cisplatin, and Radiation Therapy or Gemcitabine and Oxaliplatin in Treating Patients With Nonmetastatic Biliary Tract Cancer That Cannot Be Removed By Surgery","status":"COMPLETED","sponsor":"Federation Francophone de Cancerologie Digestive","startDate":"2005-10","conditions":"Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Liver Cancer","enrollment":34},{"nctId":"NCT00169195","phase":"PHASE2","title":"Rituximab, Gemcitabine and Oxaliplatin (R-GEMOX) for Refractory/Relapsed B-cell Lymphoma","status":"COMPLETED","sponsor":"Lymphoma Study Association","startDate":"2003-04","conditions":"Diffuse Large Cell Lymphoma","enrollment":49},{"nctId":"NCT01389414","phase":"PHASE2","title":"Panitumumab Plus Gemcitabine and Oxaliplatin (GEMOX)Versus GEMOX Alone to Treat Advanced Biliary Tract Adenocarcinoma","status":"COMPLETED","sponsor":"Prof. Massimo Aglietta","startDate":"2010-05","conditions":"Biliary Carcinoma","enrollment":89},{"nctId":"NCT01505413","phase":"PHASE2","title":"Phase 2 Study of Erlotinib, Gemcitabine and Oxaliplatin Combination Chemotherapy to Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"Soonchunhyang University Hospital","startDate":"2011-01","conditions":"Pancreatic Cancer","enrollment":33},{"nctId":"NCT00636883","phase":"PHASE2","title":"Oxaliplatin, Gemcitabine, and Erlotinib Study in Patients With Advanced Chemo-naïve Pancreatic Cancer","status":"TERMINATED","sponsor":"National Guard Health Affairs","startDate":"2008-01","conditions":"Pancreatic Cancer","enrollment":9},{"nctId":"NCT00425841","phase":"PHASE2","title":"Stereotactic Radiation Therapy and Combination Chemotherapy in Treating Patients Undergoing Surgery for Locally Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"Technical University of Munich","startDate":"2006-05","conditions":"Pancreatic Cancer","enrollment":29},{"nctId":"NCT00713687","phase":"PHASE2","title":"Gemcitabine/Oxaliplatin and Photodynamic Therapy in Cholangiocarcinoma","status":"WITHDRAWN","sponsor":"Technical University of Munich","startDate":"2008-08","conditions":"Cholangiocarcinoma","enrollment":""},{"nctId":"NCT00552149","phase":"PHASE2","title":"Biliary Cancers: EGFR INhibitor, Gemcitabine and Oxaliplatin","status":"COMPLETED","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2007-10","conditions":"Advanced Biliary Cancer","enrollment":150},{"nctId":"NCT00470340","phase":"PHASE3","title":"Chemotherapy or Not, Following Complete Treatment of Hepatic Cancer in Cirrhotic Patients","status":"TERMINATED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2007-06","conditions":"Liver Neoplasms, Liver Cirrhosis, Carcinoma, Hepatocellular","enrollment":263},{"nctId":"NCT00452881","phase":"PHASE2","title":"Adjuvant Gemcitabine Plus Oxaliplatin Versus Gemcitabine Plus Cisplatin for Completely Resected Stage IB/II/IIIA NSCLC","status":"UNKNOWN","sponsor":"National Cancer Center, Korea","startDate":"2006-05","conditions":"Lung Cancer","enrollment":151}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":37,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Gemcitabine","Oxaliplatin"],"phase":"phase_2","status":"active","brandName":"GEMOX chemotherapy","genericName":"GEMOX chemotherapy","companyName":"Prof. Massimo Aglietta","companyId":"prof-massimo-aglietta","modality":"Small molecule","firstApprovalDate":"","aiSummary":"GEMOX chemotherapy combines gemcitabine and oxaliplatin to target rapidly dividing cancer cells. Used for Advanced pancreatic cancer, Advanced ovarian cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}